药物代谢酶及转运体与前列腺癌药物治疗

药物代谢酶是催化体内摄入的各种药物进行生物转化的一系列重要酶,属于生物转化酶系中的一类.虽然药物生物转化的主要场所在肝脏,但在肝外组织(如前列腺)亦存在,而且可影响药物在局部的生物转化率.药物转运体在药物的跨膜转运中发挥了重要的作用,影响了药物在体内的药代动力学进程,药物转运体在组织中分布广泛;本文着重阐述这些药物代谢酶及转运体在治疗前列腺癌药物中的作用,及它们在前列腺中的特异性表达,同时讨论了在不同的治疗策略中与药物代谢酶及转运体相关的靶向作用.     

咖啡因体内代谢及其应用的研究进展

咖啡因是从茶叶、咖啡果中提取出来的一种生物碱,常用于治疗神经衰弱和昏迷复苏。咖啡因体内代谢过程复杂,现已发现咖啡因的15种代谢产物,参与代谢过程的酶类也被逐一证实。尿液咖啡因代谢产物比率(UCMRs)常用于多种药物代谢酶活性的评估,主要包括CYP1A2、CYP2A6、N-乙酰转移酶和黄嘌呤氧化酶,咖啡因及其代谢产物检测方法也逐步得到改进与更新。总之,咖啡因与人类健康密切相关,以及其重要的科研应用价值,一直受到普遍关注。     

药物代谢酶特异性探针底物的研发与应用进展

人体内分布数百种结构多样、功能各异的药物代谢酶,其表达和功能易受遗传和环境因素的影响,导致其在不同人种、个体及组织 中的分布都不尽相同。特异性探针底物作为药物代谢酶活性表征的关键工具分子,其在新药发现、药-药相互作用评价、临床药理学及精准 医学检测等领域具有重要的应用价值。围绕人体分布的重要药物代谢酶,综述其特异性探针底物的设计研发及生物医学应用进展,以期为 药物代谢酶的精准检测及相关应用研究提供参考。     

肿瘤中甲硫氨酸代谢及其相关基因的表达调控

甲硫氨酸(methionine)作为人体必需氨基酸,生理功能多样,在肿瘤代谢重编程过程中具有重要意义。研究发现,多种肿瘤细胞对外源性甲硫氨酸存在依赖性,该效应被称为Hoffman效应。在人体内,甲硫氨酸经甲硫氨酸循环代谢,参与一碳单位代谢、叶酸循环,以及多胺、谷胱甘肽、半胱氨酸和核苷酸等多种物质的合成。肿瘤中常出现甲硫氨酸代谢的改变,并伴随甲硫氨酸代谢相关酶基因表达的异常,其中以甲硫氨酸腺苷转移酶(methionine adenosyltransferase, MAT)相关基因表达改变及甲硫腺苷磷酸化酶(methylthioadenosine phosphorylase,MTAP)基因的缺失最为常见,二者可分别引起甲硫氨酸循环及甲硫氨酸补救合成途径的异常,进而导致甲基供体S-腺苷甲硫氨酸(S-adenosylmethionine, SAM)的生成减少和甲硫腺苷(methylthioadenosine, MTA)的堆积,其与肿瘤的发生、发展和转移等活动密切相关。由甲硫氨酸的代谢改变和代谢酶的基因表达异常,分别衍生出2种不同的治疗策略,即甲硫氨酸限制疗法和靶向治疗。本文将从甲硫氨酸代谢出发,阐述肿瘤中甲硫氨酸依懒性、肿瘤细胞MAT和MTAP相关基因的表达调控,并概述甲硫氨酸相关肿瘤治疗方案的新进展与新问题,为肿瘤治疗方案的进一步探索提供新思路。     

从Streptomyces chromofuscus ATCC 49982中鉴定出一种新型葡萄糖醛酸转移酶CSCD

糖基化是增加化合物极性的一种有效方法。UDP-葡萄糖醛酸转移酶(UGTs)在II期药物代谢中被广泛研究。然而,微生物中的UGTs没有得到很好的研究,这阻碍了这种类型的酶在天然产品的微生物葡萄糖醛酸化中的利用。     

异源物代谢核受体PXR与肿瘤多药耐药相关性的研究进展

肿瘤的多药耐药性是临床化疗中迫切需要解决的问题.孕烷X受体(pregnane X receptor,PXR)为配体活化的转录因子,其下游靶基因均为主司异源性药物/毒物生物转化功能的I相、II相代谢酶及III相转运蛋白,可对药物代谢动力学过程产生重要的影响,故有可能成为逆转肿瘤多药耐药的新的药物作用靶点.本文总结了PXR在肿瘤多药耐药中的作用及机制、新型PXR配体类药物研发等方面的研究进展.     

磺基转移酶SULT家族及其在药物代谢中的作用

硫酸化(Sulfation)是人体内主要的共轭途径之一,它们是由胞浆磺基转移酶(sulfotransferase,SULT)超家族成员催化的重要Ⅱ期反应,在人体代谢中具有重要作用。本文总结了目前人体内存在的13种SULT的组织分布和功能的相关信息,并结合目前国内外相关报道,综述了SULT在几种临床药物代谢中的影响与作用,期待为今后的药物研发和临床研究提供一定的帮助。     

代谢组学在肿瘤药物靶点筛选中的应用进展

肿瘤是一种多因素参与造成机体各系统功能平衡紊乱的代谢性疾病,代谢重编程是恶性肿瘤的重要特征之一.研究"代谢指纹图谱"的代谢组学,通过揭示肿瘤或药物引起的宿主内源性代谢物的变化,为肿瘤药物靶点的筛选提供了可能.但目前对代谢组在肿瘤药物靶点筛选中的整体性综述并不多见,因此,本文在介绍了代谢组学筛选肿瘤药物靶点的流程的基础上...     

UGT1A基因的遗传多态性对底物代谢的影响

尿苷二磷酸葡萄糖醛酸转移酶(UGT-Glucuronosyltransferase)是一种对许多内源性和外源性物质进行解毒,加强其排泄的重要酶类。UGT超基因家族分为两个大家族,即:UGT1和UGT2。研究表明,UGT1基因的遗传多态性对减轻药物的毒副作用和预测肿瘤的高危因素有重要的临床意义。     

微生物细胞色素P450与胆固醇的生物代谢

细胞色素P450(CYP450)是一类含亚铁血红素的单加氧酶,广泛存在于各类生物体内,参与多种外源物质的代谢和内源物质的转化,如甾类激素、胆汁酸、胆固醇等的代谢。胆固醇是一种环戊烷多氢菲的衍生物,也是人类重要的脂类物质和许多特殊生物活性物质的前体之一,当其过量时会导致高胆固醇血症、动脉粥样硬化、静脉血栓生成等,对机体产生不利的影响。微生物CYP450酶可催化胆固醇的生物代谢,特别是其中的CYP125酶是胆固醇分解代谢起始的关键酶,可用作调节胆固醇代谢的药物靶标。     

Nitroreduction of flutamide by Cunninghamella elegans NADPH: Cytochrome P450 reductase

The microbial model of mammalian drug metabolism, Cunninghamella elegans, has three cytochrome P450 reductase genes in its genome: g1631 (CPR_A), g4301 (CPR_B), and g7609 (CPR_C). The nitroreductase activity of the encoded enzymes was investigated via expression of the genes in the yeast Pichia pastoris X33. Whole cell assays with the recombinant yeast demonstrated that the reductases converted the anticancer drug flutamide to the nitroreduced metabolite that was also produced from the same substrate when incubated with human NADPH: cytochrome P450 reductase. The nitroreductase activity extended to other substrates such as the related drug nilutamide and the environmental contaminants 1-nitronaphthalene and 1,3-dinitronaphthalene. Comparative experiments with cell lysates of recombinant yeast were conducted under aerobic and reduced oxygen conditions and demonstrated that the reductases are oxygen sensitive.     

Preparation and characterization of subcellular fractions from the intestinal mucosa of the Northern pike (Esox lucius), with special emphasis on enzymes involved in xenobiotic metabolism

The present study was designed to prepare and characterize subcellular fractions from the intestinal mucosa of the Northern pike (Esox lucius), with special emphasis on the preparation of a microsomal fraction suitable for studying xenobiotic metabolism. The purity of the different fractions obtained by differential centrifugation, as well as the recovery of different organelles, was determined using both enzyme markers and morphological examination with the electron microscope. The subcellular distributions of several enzymes involved in drug metabolism (NADPH-cytochrome c reductase, NADH-ferricyanide reductase, epoxide hydrolase activity towards both cis- and trans-stilbene oxide as substrates, and glutathione transferase) were also examined. The subcellular distributions obtained here for drug-metabolizing and marker enzymes closely resembled those reported for rat and pike liver. The microsomal fraction obtained contained about 50% of the total endoplasmic reticulum. This fraction was relatively free of nuclei, mitochondria, Golgi, peroxisomes and cytosol, but relatively heavily contaminated with lysosomes and fragments of the plasma membrane. Within the limitations discussed, the subfractions prepared here are suitable for further characterization of drug-metabolizing systems in the intestinal mucosa of the Northern pike, as well as for other studies with this tissue.     

Drug Metabolism for the Perplexed Medicinal Chemist

Two related and significant issues may elicit perplexity in medicinal chemists and are discussed here. First, a broad presentation of the pharmacological and toxicological consequences of drug metabolism should justify the significance of drug metabolism and serve as an incentive to further study. When comparing the pharmacological activities of a drug and its metabolite(s), a continuum is found which ranges from soft drugs (no active metabolites) to prodrugs (inactive per se, as illustrated here with clopidogrel and prasugrel). Innumerable intermediate cases document drugs whose activity is shared by one or more metabolites, as exemplified with tamoxifen. The toxicological consequences of metabolism at the molecular, macromolecular, and macroscopic levels are manyfold. A brief overview is offered together with a summary of the reactions of toxification and detoxification of the antiepileptic valproic acid. The second issue discussed in the review is a comparison of the relative significance of cytochromes P450 and other oxidoreductases (EC 1), hydrolases (EC 3), and transferases (EC 2) in drug metabolism, based on a ‘guesstimate’ of the number of drug metabolites that are known to be produced by them. The conclusion is that oxidoreductases are the main enzymes responsible for the formation of toxic or active metabolites, whereas transferases play the major role in producing inactive and nontoxic metabolites.     

Chemopreventive and therapeutic modulation of green tea polyphenols on drug metabolizing enzymes in 4-Nitroquinoline 1-oxide induced oral cancer

Oral cancer is one of the most common cancers in the world. Drugs can modulate the expression of drug metabolizing enzymes and are useful in chemoprevention as well as therapy in cancer. 4-Nitroquinoline 1-oxide (4-NQO) is used to induce oral cancer in the present study. In the present investigation, the effect of green tea polyphenols (GTP) on the activities of cytochrome b5, cytochrome P450, cytochrome b5 reductase (cyt b5 R), cytochrome P450 reductase (cyt P450 R), arryl hydrocarbon hydroxylase (AHH), DT-diaphorase (DTD)(Phase I enzymes) and glutathione-S-transferase (GST) and UDP-glucuronyl transferase (UDP-GT) (Phase II enzymes) were assessed in tongue and oral cavity. In induced rats, there was a decrease in the activity of Phase II enzymes and an increase in the activity of Phase I enzymes. On supplementation of GTP by both simultaneous and post treatment mode (200mg/kg) there was a significant increase in the activity of GST and UDP-GT and a significant decrease in the activity of Phase I enzymes. There was a significant decline in the number of tumors, tumor volume and oral squamous cell carcinoma in both simultaneous and post GTP treated animals relative to 4-NQO induced animals; on comparing simultaneous and post GTP treated animals the number of tumors, tumor volume and oral squamous cell carcinoma was significantly reduced in post treated animals. Thus inhibition of Phase I enzymes could be attributed to the protective efficacy of GTP which deactivates carcinogen and GTP induced the expression of Phase II enzymes that detoxifies the 4-NQO. It can be proposed that GTP plays role as a detoxifying agent by which its modulating role prevented/inhibited the formation of tumor.     

Malic enzyme cofactor and domain requirements for symbiotic N2 fixation by Sinorhizobium meliloti

The NAD(+)-dependent malic enzyme (DME) and the NADP(+)-dependent malic enzyme (TME) of Sinorhizobium meliloti are representatives of a distinct class of malic enzymes that contain a 440-amino-acid N-terminal region homologous to other malic enzymes and a 330-amino-acid C-terminal region with similarity to phosphotransacetylase enzymes (PTA). We have shown previously that dme mutants of S. meliloti fail to fix N(2) (Fix(-)) in alfalfa root nodules, whereas tme mutants are unimpaired in their N(2)-fixing ability (Fix(+)). Here we report that the amount of DME protein in bacteroids is 10 times greater than that of TME. We therefore investigated whether increased TME activity in nodules would allow TME to function in place of DME. The tme gene was placed under the control of the dme promoter, and despite elevated levels of TME within bacteroids, no symbiotic nitrogen fixation occurred in dme mutant strains. Conversely, expression of dme from the tme promoter resulted in a large reduction in DME activity and symbiotic N(2) fixation. Hence, TME cannot replace the symbiotic requirement for DME. In further experiments we investigated the DME PTA-like domain and showed that it is not required for N(2) fixation. Thus, expression of a DME C-terminal deletion derivative or the Escherichia coli NAD(+)-dependent malic enzyme (sfcA), both of which lack the PTA-like region, restored wild-type N(2) fixation to a dme mutant. Our results have defined the symbiotic requirements for malic enzyme and raise the possibility that a constant high ratio of NADPH + H(+) to NADP in nitrogen-fixing bacteroids prevents TME from functioning in N(2)-fixing bacteroids.     

Modulatory Effect of Taurine on 7,12‐Dimethylbenz(a)Anthracene‐Induced Alterations in Detoxification Enzyme System,Membrane Bound Enzymes,Glycoprotein Profile and Proliferative Cell Nuclear Antigen in Rat Breast Tissue

The modulatory effect of taurine on 7,12‐dimethylbenz(a)anthracene (DMBA)‐induced breast cancer in rats was studied. DMBA (25 mg/kg body weight) was administered to induce breast cancer in rats. Protein carbonyl levels, activities of membrane bound enzymes (Na⁺/K⁺ATPase, Ca²⁺ATPase, and Mg²⁺ATPase), phase I drug metabolizing enzymes (cytochrome P450, cytochrome b5, NADPH cytochrome c reductase), phase II drug metabolizing enzymes (glutathione‐S‐transferase and UDP‐glucuronyl transferase), glycoprotein levels, and proliferative cell nuclear antigen (PCNA) were studied. DMBA‐induced breast tumor bearing rats showed abnormal alterations in the levels of protein carbonyls, activities of membrane bound enzymes, drug metabolizing enzymes, glycoprotein levels, and PCNA protein expression levels. Taurine treatment (100 mg/kg body weight) appreciably counteracted all the above changes induced by DMBA. Histological examination of breast tissue further supported our biochemical findings. The results of the present study clearly demonstrated the chemotherapeutic effect of taurine in DMBA‐induced breast cancer.     

Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response

Expression of P-450 (Cyp) enzymes is reduced in liver during the acute phase response, contributing to the decrease in bile acid levels and drug metabolism during infection. Nuclear hormone receptors CAR and PXR are key transactivators of Cyp2b and Cyp3a genes, respectively. Injection of bacterial lipopolysaccharide (LPS) induced the expected reduction in Cyp2b10 and Cyp3a mRNA levels in mouse liver. These decreases were associated with a marked reduction in CAR and PXR mRNA levels within 4 h following treatment. LPS-induced CAR and PXR repression were dose-dependent and sustained for at least 16 h. LPS treatment also reversed the up-regulation of Cyp3a in mice pre-treated with PXR ligand RU486. In addition, we observed a concomitant decrease in RXR (retinoid X receptor) mRNA levels, the obligatory partner of both CAR and PXR for high affinity binding to DNA. These findings represent one possible molecular mechanism underlying sepsis-induced repression of Cyp enzymes.     

Ontogeny of human hepatic cytochromes P450

Significant changes in drug-metabolizing enzyme (DME) expression occur during ontogeny. Such changes can have a profound effect on therapeutic efficacy in the fetus and child, as well as the risk for adverse drug reactions. To gain a better understanding of DME ontogeny, enzyme contents for six key cytochromes P450 were measured in 240 human liver samples representing ages from 8 weeks gestation to 18 years. Where possible, both quantitative western blotting and activity assays with probe substrates were performed. Although oversimplified, the DME can be grouped into one of three categories. As typified by CYP3A7, some enzymes are expressed at their highest level during the first trimester and either remain at high concentrations or decrease during gestation and are silenced or expressed at low levels within 1-2 years after birth. These data cause one to query whether these enzymes have an important endogenous function. Representatives of a second group, CYP3A5 and CYP2C19, are expressed at relatively constant levels throughout gestation. Postnatal increases in CYP2C19 are observed within the first year, but not for CYP3A5. CYP2C9, 2E1, and 3A4 are more typical of a third group of enzymes that are not expressed or are expressed at low levels in the fetus with the onset of expression generally in either the second or third trimester. Substantial increases in expression are observed within the first 1-2 years after birth; however, considerable interindividual variability is observed in the immediate postnatal (1-6 months) onset or increase in expression of these enzymes, often resulting in a window of hypervariability.